Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.
Peptide therapy refers to the clinical use of specific short-chain amino acid sequences — peptides — that interact with receptors, enzymes, or signaling pathways in the body to produce a desired physiological effect. Peptides are the body's own signaling language: hormones, neurotransmitters, immune modulators, and growth factors are all peptides or peptide-derived molecules. Therapeutic peptides are either identical to naturally occurring molecules (like GLP-1 agonists that mimic gut hormones) or engineered sequences designed to activate or modulate specific biological targets with precision.
Why Peptides?
Compared to small-molecule drugs, peptides offer some theoretical advantages:
- Specificity: Peptides typically bind their targets with high selectivity, potentially reducing off-target effects compared to broader pharmacological agents.
- Biological similarity: Many therapeutic peptides are identical or closely related to endogenous molecules the body already produces, which can confer a favorable tolerability profile.
- Diverse applications: The same peptide drug-development platform can be applied across metabolic disease, immune modulation, tissue repair, neurology, and endocrinology.
Disadvantages include: poor oral bioavailability (most must be injected or administered intranasally), relatively short half-lives requiring engineering solutions, manufacturing complexity, and cost.
The Regulatory Landscape
Peptide therapies span a spectrum of regulatory status:
- FDA-approved peptide drugs include semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), bremelanotide (Vyleesi), and many others — these have completed Phase I, II, and III clinical trials.
- Compounded peptides — such as BPC-157, CJC-1295, ipamorelin, and thymosin peptides — are not FDA-approved but may be legally compounded by licensed 503A pharmacies for individual patients with a valid prescription from a licensed prescriber. These are prescribed off-label based on available evidence.
- Research chemicals sold without a prescription are not appropriate for human use and fall outside the scope of legitimate medical practice.
How Peptide Therapy Works at Irvine Health
Every patient at Irvine Health begins with a licensed physician video consultation. Your provider reviews your complete medical history, current medications, relevant lab work, and personal health goals. Only after this evaluation does your physician determine whether a peptide protocol is appropriate, which compound(s) may be considered, dosing, and monitoring requirements. A written prescription is required for all compounded peptide therapies dispensed through our licensed pharmacy partners.
What to Expect
Peptide therapy is not a quick fix. Most protocols require weeks to months before meaningful physiological changes are measurable. Response varies significantly between individuals based on genetics, lifestyle, baseline health, and adherence. Ongoing monitoring — including relevant laboratory testing and provider check-ins — is a standard component of responsible peptide prescribing.
Is Peptide Therapy Right for You?
That's a question only a licensed physician can answer after reviewing your individual circumstances. Peptide therapy is not appropriate for everyone, and some conditions — active malignancy, certain autoimmune disorders, pregnancy, and others — represent contraindications to specific peptides. The consultation process exists to identify these factors and ensure that any treatment plan is safe and appropriate for you specifically.
References
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-8.
- Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707.
- FDA. Compounding and the FDA: Questions and Answers. FDA.gov. Updated 2024.
- Henninot A, et al. The Current State of Peptide Drug Discovery: Back to the Future? J Med Chem. 2018;61(4):1382-1414.